Use of emerging lipoprotein risk factors in assessment of cardiovascular risk

JAMA

Volumn 307, Issue 23, 2012, Pages 2540-2542

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE MARKER; EDITORIAL; FOLLOW UP; HEART PROTECTION; HUMAN; LIPID ANALYSIS; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

EID: 84862497464     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.6896     Document Type: Editorial

References (17)

1. The Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499-2506.
2. Contois JH, McConnell JP, Sethi AA, et al AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55(3):407-419.
3. Brunzell JD, Davidson M, Furberg CD, et al American Diabetes Association; American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822.
4. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/tencountry panel. J Intern Med. 2006;259(3):247-258.
5. Nordestgaard BG, Chapman MJ, Ray K, et al European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853.
6. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low Apolipoprotein A-I, and Improvement in the Prediction of Fatal Myocardial Infarction (AMORIS study): a prospective study. Lancet. 2001;358(9298):2026-2033. (Pubitemid 34084825)
7. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J. 2005;26(3):271-278. (Pubitemid 40222365)
8. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-345.
9. Grundy SM, Vega GL, Tomassini JE, Tershakovec AM. Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial). Am J Cardiol. 2011;108(1):40-46.
10. Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol. 1996;7(4):209-216 . Review. (Pubitemid 26280230)
11. Voight Benjamin F, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study [published online May 17, 2012]. Lancet. doi:10.1016/S0140-6736(12)60312-2.
12. Erqou S, Kaptoge S, Perry PL, et al Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and non-ascular mortality. JAMA. 2009;302(4):412-423.
13. Clarke R, Peden JF, Hopewell JC, et al PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-2528.
14. Thompson A, Gao P, Orfei L, et al Lp-PLA(2) Studies Collaboration. Lipoproteinassociated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375(9725):1536-1544.
15. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630. (Pubitemid 35379733)
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
17. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin meta-analysis of individual data from 27 randomised trials [published online May 16, 2012]. Lancet. doi:10.1016/S0140- 6736(12)60367-5.